The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Myelogenous Leukemia in Adults: An Evidence-Based Review

Relative risk (RR) of relapse or death rate comparing autologous BMT with the control arm. (Reprinted with permission; [7].)

Forrest plot of the HRs and 95% CIs for OS. Study identifications are provided below. FEM and REM denote summary HRs by the fixed-effect and random-effect models. The varying sizes of the filled diamonds represent the weight for the fixed-effect model in the meta-analysis. A hazard ratio greater than unity means that allogeneic transplantation is superior to nonallogeneic transplantation. Study IDs: 1-1: Reiffers et al. [10]; 2-1: Keating et al., Br J Haematol. 1998;102:1344-1353; 3-1 to 3-6: Slovak et al. [116]; 4-1 to 4-5: Burnett et al. [20]; 5-1 to 5-4: Suciu et al. [30]. (Reprinted with permission; [18].)

Actuarial rates of DFS of patients with AML in first complete remission according to donor availability. (Reprinted with permission; [19].)

Adjusted probability of LFS of persons 16-50 years old with AML in first remission in the IBMTR and GAMLCG databases. Numbers in parentheses indicate numbers of persons at risk at different intervals. (Reprinted with permission; [21].)

DFS from CR according to donor availability. The estimates of the 4-year DFS rates (±SE) for the donor group (dotted line) and the no donor group (solid line) are given. The 4-year cumulative incidence of relapse and of death in CR are given in italics at the right of the graph. N indicates the number of patients; O, observed number of events (relapse or death in first CR). P is determined by the log-rank test. (Reprinted with permission; [30].)

Actuarial LFS in autograft recipients with AML in CR1 treated with Bu/Cy (broken line) (n = 330) or Cy/TBI (solid line) (n = 330). The survival curves are not significantly different (P = .64). (Reprinted with permission; [77].)

Actuarial LFS in allograft recipients with AML in CR1 treated with Bu/Cy (n = 223) or Cy/TBI (n = 223). Survival curves are not significantly different (P = .63). (Reprinted with permission; [77].)

Unadjusted cumulative incidence of LFS for patients over 50 years of age with AML receiving myeloablative (MA) versus reduced intensity conditioning (RIC) prior to HLA-identical sibling HSCT. (Reprinted with permission; [87].)